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1.  Executive Summary 
 
Fifty million people around the world are currently affected by epilepsy.  Fortunately, the disease 
responds to treatment 70% of the time, but many of the medications prescribed require multiple 
dosages per day. To ensure patient compliance, prevent adverse consequences due to missed 
dosing,  and  to  enhance  medicative  convenience  for  the  patient,  Tegretol  has  engineered  as 
extended-release pill, Tegretol-XR, which delivers carbamazepine at a nearly constant rate for a 
twelve hour time period.  The design of these tablets involves a drug infused matrix surrounded 
by an insoluble shell, with a small orifice to allow drug release.  When water diffuses through the 
orifice, the interior pill matrix saturates, and carbamazepine begins to elute out of the orifice 
until depletion, a process that is designed to take twelve hours. 
 
Using COMSOL, a Tegretol-XR tablet was modeled as a 2D rectangular, axisymmetrical slab. 
Researched diffusivity constants were found to precisely model the water and drug flow into and 
out of the pills. The diffusion of the drug is coupled with the concentration of water, and as the 
water infuses into the pill, the diffusivity of the drug is altered, ultimately leading to a sustained 
release of carbamazepine over the allotted twelve hours. Results from our model indicate that 
drug release closely follows ideal release kinetics and keeps an ample amount of drug in the 
bloodstream at all times. It was found that altering the orifice size by 5% resulted in changes of 
up to 16% in final average drug concentration, implicating that this is the most sensitive variable 
analyzed. Variables like water diffusivity were much less influential to the final solution. Our 
model of Tegretol-XR gives epileptic patients the option of taking only two pills a day, and thus, 
significantly lowers the risk of a missed dose. -2- 
2.  Introduction 
 
Epilepsy has afflicted human beings for thousands of years and has been acknowledged in even 
the earliest medical writings. Despite its long-standing presence, the disease generated much 
controversy  –  with  people  in  the  late  1400s  citing  the  appearance  of  seizures  as  a  way  of 
identifying witches. Some states even required sterilization for all epileptic patients during the 
early 1900s. After much attention and debate, it was finally understood that epilepsy is a group 
of disorders that occurs as a result of seizures that temporarily impair brain function. Seizures 
can alter consciousness, sensation, and behavior [1]. 
 
Epilepsy currently affects approximately 50 million people in the world. Approximately 90% of 
these people are from developing regions. While 70% of epilepsy cases respond to treatments, 
about 75% of people in developing regions never receive this treatment [2]. Additionally, the 
compliance  rates  for  three-times-a-day  and  four-times-a-day  dosing  are  75%  and  50% 
respectively, leading to patients missing doses, which could lead to fatal consequences [2]. An 
anti-convulsant, carbamazepine is taken by epileptic patients to control their seizures. While 
many brands exist, few address the problem that these pills must be taken 3 or 4 times a day. 
 
The leading brand of carbamazepine in the United States is Tegretol. The brand‟s extended-
release tablets, denoted by an „XR‟, eliminate the need to take multiple pills in one day and thus 
significantly lower the risk of a missed dose. The XR tablets work by using diffusion of water 
and  carbamazepine  through  a  small  hole  in  the  tablets.  When  water  enters  the  tablet,  it 
determines  the  rate  of  carbamazepine  diffusion  out  of  the  hole,  and  this  diffusion  can  be 
sustained for long time periods. Using computer-aided engineering, we will be able to model 
precisely the mechanism of how fluid enters the tablet‟s outer shell, causing the rate of drug 
diffusion to change and ultimately leading to a sustained, controlled-release of carbamazepine 
over an allotted period of time.  -3- 
3.  Design Objectives 
 
We are interested in modeling the extended-release of 400mg of Tegretol-XR over a twelve hour 
period.  In order to optimize a controlled diffusion of the drug out of the pill, the rate of diffusion 
of  water  through  the  pill‟s  matrix  must  be  determined.  Once  both  diffusivities  and  their 
relationship are ascertained, the mass transfer problem can be modeled over a twelve hour period 
with COMSOL. 
 
3.1  Problem Schematic 
 
In order to meet our objectives, the pill was modeled as a 2-D rectangular, axisymmetric slab.  
The schematic shown below depicts the pill geometry and dimensions, as well as the dimensions 
of the orifice (Figure 1).  The governing equation, boundary conditions, and initial conditions are 
listed in Appendix A.  In addition, our finalized mesh along with the mesh convergence used to 
determine its ideal element size is located in Appendix B. 
 
 
 
Figure 1: Schematic of COMSOL model 
The pill dimensions and geometry are based on observation; orifice size was based on Lu et al. 
[3]. 
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4.  Results and Discussion 
 
During our COMSOL analysis, we determined the concentrations of drug and water at different 
time points during a twelve hour trial.  Our project is primarily focused on optimization of a 
constant and controlled-release of drug over a twelve hour period.  Ideally, this relationship 
would be a straight line on a graph of drug released versus time, culminating in total drug release 
after twelve hours.  Because the massive influx of water alters the diffusive properties of the 
drug  itself,  accomplishing  the  ideal  release  curve  is  impossible.    However,  by  careful 
optimization  of  the  drug  and  water  diffusivities  throughout  our  pill  matrix,  our  model  has 
approached the ideal mechanism of controlled-release drug delivery.   
 
Our model‟s performance with regards to water influx and drug release can be found in Figure 2.  
The  drug  release  curve  closely  follows  ideal  release  kinetics,  and  also  maintains  an  ample 
amount of drug in the bloodstream. 
 
 
Figure 2: Percent of Water Saturation and Drug Release over Time 
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Tegretol-XR is known to be released over a twelve hour period [4].  Water first enters the pill via 
the orifice and this influx alters the release kinetics of the drug.  As soon as the pill is saturated 
with water, the drug begins to release at a steadier and faster rate.  While the drug is releasing, its 
concentration throughout the matrix steadily diminishes and this ultimately curbs the speed at 
which drug diffuses out of the orifice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Flux of Water at Orifice (r=0, z=0.0029) Over 12 hours 
The water quickly permeates throughout the pill and due to its higher diffusivity, the pill is soon 
saturated.  The relation between the water and drug diffusion is most readily apparent at the 
climax of water diffusion and can be witnessed on the drug diffusivity graph by a small „blip‟. 
 
In  this  drug  delivery  mechanism,  water  quickly  enters  the  pill  due  to  its  higher  diffusivity, 
causing the pill to become saturated (Figure 3).  This is very important when modeling drug 
diffusion, because the sudden rush of water into the pill makes it difficult for large amounts of 
drug to be released.  As a result, the flux of drug out of the orifice stalls until the inward water 
flux reaches a maximum and abruptly drops.  Figure 4 illustrates the flux of drug out of the 
orifice over the twelve hour period.  Once the maximum flux of water has been attained, the drug 
flux increases rapidly and then drops much more gradually.  This phenomenon is simply due to -6- 
the diffusivity characteristics of the drug and its lingering concentration embedded within the 
matrix. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Flux of Drug at Orifice (r=0, z=0.0029) Over 12 hours 
The small blip at the beginning of the graph coincides with the sudden decline in diffusive flux 
of water with which the drug‟s diffusivity is intimately related. 
 
Further evidence of controlled-release of drug out of the pill and water into the pill are depicted 
by the cross-sectional plots in Appendix C.  Figure C3 illustrates an increase of water into the 
pill  over time, while Figure C4 shows a constant  linear decrease  of the drug concentration.  
Contour plots also located in Appendix C illustrates that the pill becomes completely saturated 
with water after 12 hours and that almost all of the drug is released over the same amount of time 
(Figures C1, C2). 
 
4.1  Accuracy Check 
 
In order to validate our data we compared our results with a solution denoted in the J. Siepmann 
et al. paper [5].  The Siepmann et al paper depicted an experiment with similar release kinetics to 
our model.  Also included within the paper is drug flux data that is comparable to our Figure 2 
plot of pill saturation over time (Figure 5A, B).  The results published within this academic -7- 
journal are highly correlative with our model‟s final release data, hence validating our model.  
 
 
Figure 5A, B: Model validation from scientific literature. 
(A) shows the percent of saturation in pill over course of 20 hours. (B) shows percent of total 
drug released in pill over course of 20 hours [5]. These results correlate well with our model, 
thus validating it. 
 
 
4.2  Sensitivity Analysis 
 
To determine which parameters most greatly influenced our final result, a sensitivity analysis 
was performed.  This analysis is important to future researchers looking to reproduce our result.  
Additionally, it is imperative to understand how to alter our model to best fit patient needs.  We 
can use the sensitivity analysis to determine which variables to vary in order to obtain major or 
minor differences in the average concentration of drug following a twelve hour release. 
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Figure 6: Average Drug Concentration with ± 5% Variation in Drug Diffusivity, Orifice 
Size, and Water Diffusivity 
We adjusted three different parameters to our model to see their effect on the final result. 
Varying orifice size and varying drug diffusivity had a negative correlation with the final drug 
concentration at 12h, while varying water diffusivity did not show conclusive results. 
 
Figure 6 shows that our model is most sensitive to orifice size variation. A five percent increase 
in orifice size results in an overall 16% reduction in final drug concentration.  There is also a 
steady and significant decrease in average drug concentration when drug diffusivity is altered.  A 
five percent increase in drug diffusivity results in a 10% decrease in final drug concentration. 
Lastly, we considered  water diffusivity as  a sensitive variable in  our model. A five percent 
difference in water diffusivity has a very small change in final drug concentration, and therefore 
we can conclude it is the least sensitive variable.  In order to further conclude that water‟s 
diffusivity is the least sensitive, we modified it by ten percent and there remained only a 1.8% 
change in final drug concentration. -9- 
 
Figure 7:  Sensitivity analysis of the drug flux in relation to a 5% difference in orifice size 
To achieve a more constant flux, we investigated how the orifice size changes the shape of the 
flux curve. Decreasing orifice size results in a slightly smoother curve, but also releases less of 
the drug overall. 
 
 
Figure 8:  Actual amount of drug released with respect to 5% sensitivity analysis on orifice 
size 
We also investigated the amount of drug released over time and observed that decreasing orifice 
size results in a more steady release, but less amount released over 12 hours. -10- 
Since orifice size is the most sensitive solution-dependent variable, the drug flux and total drug 
released were plotted versus time in Figures 7 and 8.  It is apparent from these two graphs that a 
5% difference in orifice size has definitive consequences to the release kinetics, although all 
three plotted data sets follow a similar trend for the twelve hour time period. 
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Figure 9: Amount of drug released with respect to 25% and 50% reductions in orifice size  
We further investigated the effects of reducing the orifice size and observed that the reduction 
resulted in a more linear release, but less total drug was released over 12 hours. 
 
Because  decreasing  the  orifice  size  appeared  to  result  in  a  more  linear  release  of  drug,  we 
reduced the opening by 25% and 50%.  While we found the release rate to be more ideal, we also 
found that the total amount of drug released was significantly less than 400mg.  Figure 9 clearly 
indicates that a non-therapeutic level of drug will be released over the span of 12 hours.  Further 
optimization of the ideal release kinetic would result in the drug releasing medication for longer 
periods of time and ultimately would result in a less controlled release.  Our initial objectives 
require a controlled release of 400mg of  carbamazepine over a twelve hour period, and the 
reduction in orifice sizes does not fulfill this objective. 
 
 -11- 
5.  Conclusion and Design Recommendations 
 
The goal of this project was to model the anti-convulsant drug release from an extended-release 
Tegretol pill.  For this tablet, the drug is eluted from the pill by osmotic pressure from water 
saturation.  We modeled this by using a drug diffusion rate that was inherently related to the 
instantaneous water concentration.  Due to a large water diffusivity value, water saturated the pill 
swiftly and this led to a steady release of Tegretol-XR over a twelve hour period, confirming the 
controlled-release mechanism of our pill.  Sensitivity analysis performed at the conclusion of our 
experiment indicated that drug diffusivity and orifice size are the most sensitive variables in our 
model.  Furthermore, the water diffusivity was determined to be the least sensitive variable, and 
did not have an overtly substantial effect on final drug concentration.  While decreased orifice 
size did indeed result in a more steady release, it did not fulfill our design objective.  Using an 
orifice size of 1.25 mm results in the most ideal release of 400mg of carbamazepine over a 
twelve hour period.  Since this  is  our primary objective, further  reduction of orifice size is 
deemed unnecessary. 
 
In order to design the ideal extended-release anti-convulsant pill for epileptic patients, many 
factors must be taken into account.  The pill must be manufactured and tested so that controlled-
release  is  an  attainable  goal.   According  to  our  sensitivity  analysis,  manufacturability  issues 
when drilling the small opening are very important.  The orifice must be made a specific size in 
order to not heavily influence the amount of drug released.  Also, it is very important that the 
patient does not chew the pill, which would completely ruin the extended-release mechanism.  
The biological implications of ingesting a drug that stays in the bloodstream for a long period of 
time must also be investigated. 
 
Based on our analysis of Tegretol-XR, we find that this brand succeeds in achieving a controlled-
release  of  therapeutic  levels  of  carbamazepine  into  the  human  body.  While  decreasing  the 
orifice  size  results  in  a  more  linear  release  of  drug,  the  total  amount  of  drug  released  also 
becomes significantly  less.   Taking these  factors  into account,  we suggest  that Tegretol-XR 
retain its specific orifice size because therapeutic levels of drug are maintained in the body at all 
times, even though a constant rate of release is not achieved. -12- 
Appendix A: Mathematical Statement of the Problem 
 
Through research of drug diffusivity and its relation to water concentration we found a paper for 
a similar time-release mechanism [5].  The paper included the following relations: 
 
 
Where β1 and β2  are constants that represent concentration dependence. C1eq is the water 
concentration at swelling point and D1eq and D2eq are the diffusivities of water and drug in the 
equilibrium swollen state of the system; basically, the time where the water has completely 
infiltrated the pill and begins to push drug out. β1=2.5  and β2  =9.5. D1eq =5.6 x 10
-9 m
2/s and 
D2eq= 6.3 x 10
-10m
2/s. C1 is the independent variable. 
 
 
Table of Properties 
Property/Parameter Name  Value  Source 
Diffusivity of Water at Equilibrium (D1eq & Dw)  5.6 x 10
-9 m
2/s  Siepmann, T. et al. 1999 [5] 
Diffusivity of Drug at Equilibrium (D2eq & DD)  6.3 x 10
-10m
2/s  Siepmann, T. et al. 1999 [5] 
Porosity of Pill Matrix  0.6  Durig, T. et al. 1999 [6] 
Concentration of Water at Swelling Point, or 
when fully saturated (C1eq) 
CW = 33000 
mol/m
3 
Porosity * density of water 
Constants 
Concentration Dependent Constant 1 (β1)  2.5  Siepmann, T. et al. 1999 [5] 
Concentration Dependent Constant 2 (β2 )   9.5  Siepmann, T. et al. 1999 [5] 
Variables and Solvers 
Concentration of Drug  cD   
Concentration of Water  cW   
Time  t   
Distance in Radial and Vertical Directions  r and z   
 
Governing equations:  
Water:  
 
 
 
Drug: 
 
 
 
 -13- 
 
 
Initial conditions: 
cw ( t = 0 ) = 0 mol/mm
3;  
 
cD ( t = 0 ) = 2.553 mg/mm
3;  *For 400 mg dose 
 
 
Boundary conditions:  
Outside of pill:   FluxW = 0
 
 
      FluxD = 0
 
 
Axis of symmetry:   FluxW = 0
 
 
      FluxD = 0
 
 
Opening:     CW = 33000 mol/m
3 
 
      CD = 0  -14- 
Appendix B: Solution Strategy 
 
Our problem was solved using the direct finite element method because our schematic has a 
simple, 2D geometry and thus, does not require the iterative method. 
 
For  this  problem,  we  used  a  constant  time  step  of  1000  seconds  to  model  water  and  drug 
diffusion into and out of the pill.  This was sufficient for modeling since we wanted to observe 
the release of drug over an extended period of time. 
 
The transient nature of this problem led COMSOL to use both a relative and absolute tolerance.  
We used the default value of 0.01 for relative tolerance and 0.0010 for the absolute tolerance.  
Given  that  our  problem  was  not  exceptionally  complex,  the  default  COMSOL  values  were 
sufficient for modeling release of carbamazepine from the pill. 
 
A 1D, 2-noded element was used for the mesh.  Figures B1 and B2 below illustrate the final 
mesh used as well as the mesh convergence. 
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Figure B1:  Finalized Mesh 
Our finalized mesh consists of 4465 elements.  This was determined using the mesh convergence 
detailed in Figure 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B2: Mesh Convergence for Amount of Drug Remaining at t=12 hours 
Our mesh convergence analysis compares the number of mesh elements to total mg of drug 
remaining at 12 hours.  Based on the graph above, we see that convergence occurs around 3000 
mesh elements.  At this point, our solution is no longer dependent on the mesh. 
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Appendix C: Additional visuals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C1: Contour Plot at t=12 hours of Drug Concentration at the Surface of Pill 
This contour plot shows that after 12 hours there is only a small amount of drug left in the pill. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C2: Contour Plot at t=12 hours of Water Concentration at the Surface of Pill 
This contour plot shows that after a 12 hour period water has completely infiltrated the pill. 
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Figure C3: Cross-sectional Plot of Water Concentration at r=2.5mm, z=1.5mm 
Increasing concentration over time is exhibited, with the plot leveling out near the initial 
concentration of water, confirming complete saturation and the effects of a changing water 
concentration gradient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C4: Cross-sectional Plot of Drug Concentration at r=2.5mm, z=1.5mm 
Drug concentration decrease is approximately linear over 12 hours.-18- 
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